Ranjan Pathak1, Anjan Katel2, Erminia Massarelli1, Victoria M Villaflor1, Virginia Sun3, Ravi Salgia1. 1. Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA. 2. Department of Medicine, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal. 3. Department of Population Science, City of Hope, Duarte, California, USA.
Abstract
BACKGROUND: The development of immune checkpoint inhibitors (ICIs) represents a paradigm shift in the treatment of cancers. Despite showing remarkable efficacy, these agents can be associated with life-threatening immune-related adverse events. In recent years, several cases of myocarditis with myositis and/or myasthenia gravis overlap syndrome (IM3OS) have been reported. However, given the rarity, the clinical features and outcomes of these cases remain poorly understood. We, therefore, attempted to systematically review and summarize all cases of IM3OS reported in the literature. MATERIALS AND METHODS: Studies reporting IM3OS were identified in Embase and MEDLINE. Only case reports and case series published in journals or presented at conferences were included. We conducted a systematic review according to the PRISMA Harms guidelines. RESULTS: A total of 60 cases were eligible. The patients' median age was 71 years, and the majority (67%) were males; melanoma was the most common indication for ICIs (38%). The most-reported symptoms were fatigue (80%) and muscle weakness (78%). The median number of doses to the development of IM3OS was one. The average creatine kinase level was 9,645 IU/L. Cardiac arrhythmias occurred in 67% of patients, and 18% had depressed ejection fraction. Initial treatment consisted of immunosuppression with high-dose steroids and supportive therapies. Sixty percent of the patients died in hospital because of acute complications. CONCLUSION: IM3OS can be associated with significant mortality and morbidity. Prospective studies are needed to understand the optimal approach to diagnose and manage these patients and to develop biomarkers to predict the occurrence and severity of this rare but serious condition. IMPLICATIONS FOR PRACTICE: Clinicians should suspect coexisting myositis and/or myasthenia gravis in all patients with immune checkpoint inhibitor-induced myocarditis, given their propensity to occur together. Early recognition and prompt treatment with the help of a multidisciplinary team might help improve the outcomes of this life-threatening condition.
BACKGROUND: The development of immune checkpoint inhibitors (ICIs) represents a paradigm shift in the treatment of cancers. Despite showing remarkable efficacy, these agents can be associated with life-threatening immune-related adverse events. In recent years, several cases of myocarditis with myositis and/or myasthenia gravis overlap syndrome (IM3OS) have been reported. However, given the rarity, the clinical features and outcomes of these cases remain poorly understood. We, therefore, attempted to systematically review and summarize all cases of IM3OS reported in the literature. MATERIALS AND METHODS: Studies reporting IM3OS were identified in Embase and MEDLINE. Only case reports and case series published in journals or presented at conferences were included. We conducted a systematic review according to the PRISMA Harms guidelines. RESULTS: A total of 60 cases were eligible. The patients' median age was 71 years, and the majority (67%) were males; melanoma was the most common indication for ICIs (38%). The most-reported symptoms were fatigue (80%) and muscle weakness (78%). The median number of doses to the development of IM3OS was one. The average creatine kinase level was 9,645 IU/L. Cardiac arrhythmias occurred in 67% of patients, and 18% had depressed ejection fraction. Initial treatment consisted of immunosuppression with high-dose steroids and supportive therapies. Sixty percent of the patients died in hospital because of acute complications. CONCLUSION: IM3OS can be associated with significant mortality and morbidity. Prospective studies are needed to understand the optimal approach to diagnose and manage these patients and to develop biomarkers to predict the occurrence and severity of this rare but serious condition. IMPLICATIONS FOR PRACTICE: Clinicians should suspect coexisting myositis and/or myasthenia gravis in all patients with immune checkpoint inhibitor-induced myocarditis, given their propensity to occur together. Early recognition and prompt treatment with the help of a multidisciplinary team might help improve the outcomes of this life-threatening condition.
Authors: John A Thompson; Bryan J Schneider; Julie Brahmer; Stephanie Andrews; Philippe Armand; Shailender Bhatia; Lihua E Budde; Luciano Costa; Marianne Davies; David Dunnington; Marc S Ernstoff; Matthew Frigault; Benjamin H Kaffenberger; Matthew Lunning; Suzanne McGettigan; Jordan McPherson; Nisha A Mohindra; Jarushka Naidoo; Anthony J Olszanski; Olalekan Oluwole; Sandip P Patel; Nathan Pennell; Sunil Reddy; Mabel Ryder; Bianca Santomasso; Scott Shofer; Jeffrey A Sosman; Yinghong Wang; Ryan M Weight; Alyse Johnson-Chilla; Griselda Zuccarino-Catania; Anita Engh Journal: J Natl Compr Canc Netw Date: 2020-03 Impact factor: 11.908
Authors: Houssein Safa; Daniel H Johnson; Van Anh Trinh; Theresa E Rodgers; Heather Lin; Maria E Suarez-Almazor; Faisal Fa'ak; Chantal Saberian; Cassian Yee; Michael A Davies; Sudhakar Tummala; Karin Woodman; Noha Abdel-Wahab; Adi Diab Journal: J Immunother Cancer Date: 2019-11-21 Impact factor: 13.751
Authors: Jutta Bergler-Klein; Peter P Rainer; Markus Wallner; Marc-Michael Zaruba; Jakob Dörler; Armin Böhmer; Tamara Buchacher; Maria Frey; Christopher Adlbrecht; Rupert Bartsch; Mariann Gyöngyösi; Ursula-Maria Fürst Journal: Wien Klin Wochenschr Date: 2022-05-04 Impact factor: 2.275
Authors: Anna M Czarnecka; Marcin Kleibert; Iga Płachta; Paweł Rogala; Michał Wągrodzki; Przemysław Leszek; Piotr Rutkowski Journal: J Clin Med Date: 2022-09-01 Impact factor: 4.964
Authors: François Deharo; Julien Carvelli; Jennifer Cautela; Maxime Garcia; Claire Sarles; Andre Maues de Paula; Jérémy Bourenne; Marc Gainnier; Amandine Bichon Journal: J Clin Med Date: 2022-09-23 Impact factor: 4.964